Thomas Oellerich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Oellerich has a total of 631 co-authors. Here are the top co-authors by number of shared publications:
- Louis M. Staudt
Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
126 shared publications - Sebastian Scheich
Department of Hematology and Oncology, University Hospital Frankfurt, Frankfurt am Main, Germany
105 shared publications - James D. Phelan
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
104 shared publications - George W. Wright
Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD
93 shared publications - Jagan Muppidi
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
83 shared publications - Björn Häupl
University Hospital Frankfurt 3 Department of Medicine, Hematology and Oncology Goethe University Frankfurt, Frankfurt am Main, Germany
80 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
PPP1R2-BioID2 Log2 fold enrichment versus empty vector in RPMI 8226 and XG7 MM cell lines.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
PPP1R2-BioID2 Log2 fold enrichment versus empty vector in RPMI 8226 and XG7 MM cell lines.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
LZTR1-BioID2 Log2 fold change enrichment over BioID2 empty vector in RPMI 8226 and XG7 cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
LZTR1-BioID2 Log2 fold change enrichment over BioID2 empty vector in RPMI 8226 and XG7 cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Key resources table, including all antibodies, cell lines, and reagents used in this study.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Key resources table, including all antibodies, cell lines, and reagents used in this study.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Patient demographic information.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Patient demographic information.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
All gene fragments used for cloning in this study.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
All gene fragments used for cloning in this study.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable. Significance:We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation.See related commentary by Boise, p. 860
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable. Significance:We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation.See related commentary by Boise, p. 860
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Supplementary Figure 1. PPP1R2 and PP1C regulate RAS stability. Supplementary Figure 2. T148 of KRAS is directly targeted by PP1C. Supplementary Figure 3. PPP1R2 and PP1C regulate RAS ubiquitination. Supplementary Figure 4. A146 mutations protect KRAS from LZTR1-mediated degradation. Supplementary Figure 5. PPP1R2 and PP1C control NRAS stability. Supplementary Figure 6. PAK1/2 inhibition blocks T148 phosphorylation.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Supplementary Figure 1. PPP1R2 and PP1C regulate RAS stability. Supplementary Figure 2. T148 of KRAS is directly targeted by PP1C. Supplementary Figure 3. PPP1R2 and PP1C regulate RAS ubiquitination. Supplementary Figure 4. A146 mutations protect KRAS from LZTR1-mediated degradation. Supplementary Figure 5. PPP1R2 and PP1C control NRAS stability. Supplementary Figure 6. PAK1/2 inhibition blocks T148 phosphorylation.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Results from 3 independent KRAS stability screens. Left: Log2 fold enrichment of mNG-KRASG12D low and high subpopulations over input; Right: overall averages and computed KRAS stability scores with p-values.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Results from 3 independent KRAS stability screens. Left: Log2 fold enrichment of mNG-KRASG12D low and high subpopulations over input; Right: overall averages and computed KRAS stability scores with p-values.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
BioID2-KRAS G12D with T148A vs. T148D mutations expressed in XG7 MM cell lines.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
BioID2-KRAS G12D with T148A vs. T148D mutations expressed in XG7 MM cell lines.
- Open Access
- 31 August 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (6) , 978-998
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable. Significance: We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation. See related commentary by Boise, p. 860
- 31 August 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (6) , 978-998
Open AccessPhosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable. Significance: We found that PP1C and PAK1/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation. See related commentary by Boise, p. 860